Efficacy and safety of prehospital fibrinogen early in severe trauma study: A feasibility phase II study (PRE-FEISTY II) (Stage 1).

When someone suffers a serious injury and is losing a lot of blood, their body's ability to clot that blood can become severely impaired — making the bleeding much harder to stop. Fibrinogen is a protein that plays a key role in blood clotting, and giving extra fibrinogen early may help control bleeding before the patient even reaches the hospital. This study is testing whether it is practical and safe to give fibrinogen concentrate to seriously injured patients in the ambulance, before they arrive at hospital. The study is a feasibility trial, meaning it is designed to find out whether running a larger definitive trial in the prehospital setting is practical and to gather early safety data. Participants will be seriously injured adults who are already receiving blood transfusions in the ambulance. You may be eligible if you are an adult (18 or older) who has sustained a serious injury with ongoing bleeding and is already receiving blood products before reaching hospital. Patients whose injuries are incompatible with survival, who are known to be pregnant, who have blood clotting disorders, or who object to blood products are not eligible.